The Real-World Endeavor Resolute vs. Xience V Drug-Eluting Stent Study in Twente trial compared 5-year outcomes in patients with coronary lesions assigned to a zotarolimus-eluting stent (ZES; Resolute, Medtronic) or an everolimus-eluting stent (EES; Xience V, Abbott Vascular).

Design: Randomized, single blind, parallel-assignment

Patients: 1,709

Centers: Single

Countries: The Netherlands

Results: At 5 years, the rate of target vessel failure was 16.1% in the ZES group vs. 18.1% in the EES group (P = .36). Definite stent thrombosis occurred in 1% of the ZES group and 0.6% of the EES group (P = .37). Compared with patients enrolled in the trial, eligible patients not enrolled had similar rates of MI (P = .8) and target vessel revascularization (P = .36) but were older, had more advanced disease, had a higher rate of TVF (P = .02) and a higher rate of cardiac death (P = .03).

Original Publications:
Von Birgelen C, et al. JAMA Cardiol. 2017;doi:10.1001/jamacardio.2016.5190.

Healio/Cardiology News Coverage:
Long-term results indicate safety, efficacy of two newer-generation DES